Literature DB >> 30999145

Establishing treatment optimisation as part of personalised medicine development.

Denis Lacombe1, Gianluca Quaglio2, Stéphane Lejeune3, Robbe Saesen3, Paul Rübig4.   

Abstract

Year:  2019        PMID： 30999145     DOI： 10.1016/j.ejca.2019.03.014

Source DB:  PubMed          Journal:  Eur J Cancer        ISSN： 0959-8049            Impact factor:   9.162


× No keyword cloud information.
  3 in total

1.  How do cancer clinicians perceive real-world data and the evidence derived therefrom? Findings from an international survey of the European Organisation for Research and Treatment of Cancer.

Authors:  Robbe Saesen; Georgios Kantidakis; Ann Marinus; Denis Lacombe; Isabelle Huys
Journal:  Front Pharmacol       Date:  2022-08-24       Impact factor: 5.988

2.  How to balance valuable innovation with affordable access to medicines in Belgium?

Authors:  Steven Simoens; Khadidja Abdallah; Liese Barbier; Teresa Barcina Lacosta; Alessandra Blonda; Elif Car; Zilke Claessens; Thomas Desmet; Evelien De Sutter; Laurenz Govaerts; Rosanne Janssens; Teodora Lalova; Evelien Moorkens; Robbe Saesen; Elise Schoefs; Yannick Vandenplas; Eline Van Overbeeke; Ciska Verbaanderd; Isabelle Huys
Journal:  Front Pharmacol       Date:  2022-09-16       Impact factor: 5.988

3.  Views of European Drug Development Stakeholders on Treatment Optimization and Its Potential for Use in Decision-Making.

Authors:  Robbe Saesen; Stéphane Lejeune; Gianluca Quaglio; Denis Lacombe; Isabelle Huys
Journal:  Front Pharmacol       Date:  2020-02-05       Impact factor: 5.810
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.